Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00384215 · ClinicalTrials.gov registry record · Phase 4
Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin
A Phase 4 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 4
- Development phase
- 352
- Enrollment target
NCT00384215: Completed Phase 4 study, sponsored by Sanofi.
NCT00384215 is a Phase 4 study that has completed, run by Sanofi. The registered enrollment target is 352 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00384215, a Phase 4 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 352 participants
- Enrollment target
Study Summary
This trial will explore the various advantages and possible disadvantages of pioglitazone and insulin glargine when added to monotherapy. Glycemic control, hypoglycemia, weight, lipid profiles, quality of life and cost will be studied given a comprehensive set of data that may help future treatment decisions.
Interventions
- DRUG insulin glargine [rDNA origin] injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 352 participants |
| Start Date | 2001-12 |
| Est. Completion | 2005-02 |
| Phase | Phase 4 |
What the finished NCT00384215 record still lists
NCT00384215 is an interventional study that assigns participants to a tested intervention. The registered 352 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 1 intervention - of which insulin glargine [rDNA origin] injection is the first listed.
NCT00384215 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00384215 about?
NCT00384215 is a clinical study titled "Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin". This trial will explore the various advantages and possible disadvantages of pioglitazone and insulin glargine when added to monotherapy. Glycemic control, hypoglycemia, weight, lipid profiles, quality of life and cost will be studied given a comprehensive set of data that may help future treatment ...
What is the current status of trial NCT00384215?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 352 participants. The study started on 2001-12. Estimated completion is 2005-02.
What interventions are being tested in trial NCT00384215?
The interventions under investigation include: insulin glargine [rDNA origin] injection (DRUG).
Who is sponsoring clinical trial NCT00384215?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00384215's enrollment target sits among peer trials
352 229th of 2000 higher than 1,771 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05811936 · 352 participants · NA
The SNAP Tool for Head and Neck Cancer Survivor-Caregiver Dyads
- NCT06258941 · 352 participants · Phase 1
Classroom Break, Cognition, and Fitness in Elementary School Children
- NCT06269081 · 352 participants · NA
Testing Two Interventions to Improve Health Outcomes and Quality of Life Among Rural Older Adults Living With HIV
- NCT06337292 · 352 participants · Phase 3
Incisional Negative Pressure Wound Therapy to Reduce Infection and Complications in High-Risk Fractures
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia